DelveInsight’s “Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Small Cell Lung Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Non-Small Cell Lung Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Small Cell Lung Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Small Cell Lung Cancer (NSCLC): An Overview
NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinoma, squamous cell carcinomas, large cell carcinomas, and several other types that occur less frequently including adenosquamous carcinomas, and sarcomatoid carcinomas.
NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinoma may also be found in patients who have never smoked.
NSCLC is relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC. Patients of NSCLC with the resectable disease may be cured by surgery or surgery followed by chemotherapy. Local control can be achieved by radiation therapy in a large number of patients with unresectable disease.
Currently, the mainstay of treatment is immune checkpoint inhibitors, the combination of targeted immunotherapy with chemotherapy. However, in the future, the scenario is going to be changed as most of the companies are targeting specific mutations to treat NSCLC patients.
Non-Small Cell Lung Cancer (NSCLC) Market Key Facts
-
As per DelveInsight’s analysis, the total Non-Small Cell Lung Cancer incident cases in the 7MM were approximately 500,000 cases in the year 2022 which is expected to reach approximately 600,000 cases in the year 2032.
-
In the US for 2023, there are approximately 200,000 new cases of lung cancer (117,550 in men and 120,790 in women) are expected to occur.
-
The three main histological subtypes of Non–Non-small cell Lung Cancer are Adenocarcinoma, Squamous cell carcinoma, and Large cell (undifferentiated) carcinoma. About 40% of all lung cancers are adenocarcinomas. About 25-30% of all lung cancers are Squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 10-15% of all lung cancers.
-
According to the research study of Serizawa et al. (2014), the stage-specific diagnosed cases were observed to be approximately 25%, 7%, 21%, and 46% for Stage I, Stage II, Stage III, And Stage IV cases of NSCLC.
Non-Small Cell Lung Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Small Cell Lung Cancer pipeline therapies. It also thoroughly assesses the Non-Small Cell Lung Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Non-Small Cell Lung Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Non-Small Cell Lung Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-Small Cell Lung Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Non-Small Cell Lung Cancer Epidemiology, Segmented as –
-
Total incident cases of Non-small Cell Lung Cancer
-
Total incident cases of Non-small Cell Lung Cancer by histology
-
Total cases of Non-small Cell Lung Cancer by stages
-
Total incident cases of Non-small Cell Lung Cancer by genetic mutation/biomarkers
-
Total treated cases of Non-small Cell Lung Cancer by the line of therapies
Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to be launched during the study period. The analysis covers the Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-Small Cell Lung Cancer drugs based on their sale and market share.
The report also covers the Non-Small Cell Lung Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-Small Cell Lung Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Non-Small Cell Lung Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Analysis
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
To recommend a treatment option to a patient with NSCLC, several key factors are taken into consideration, such as age of the patient, previous medical history, health status, and smoking history. Along with those, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. Furthermore, biological testing of the tumor is also crucial to understanding the presence of specific mutations.
Several major pharma and biotech companies are developing therapies for Non-Small-Cell Lung cancer (NSCLC). Currently, Daiichi Sankyo is leading the therapeutics market with its Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage of clinical development.
Non-Small Cell Lung Cancer (NSCLC) Companies Actively Working in the Therapeutics Market Include
BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and many others.
Emerging and Marketed Non-Small Cell Lung Cancer (NSCLC) Therapies Covered in the Report Include:
-
JDQ443: Novartis
-
MRTX849: Mirati Therapeutics
-
INBRX-106: Inhibrx
-
KEYTRUDA (pembrolizumab): Merck
-
LIBTAYO (cemiplimab-rwlc): Regeneron Pharmaceuticals
-
Telisotuzumab Vedotin (Teliso-V): AbbVie
-
Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis
4. Non-Small Cell Lung Cancer Market Overview at a Glance
5. Non-Small Cell Lung Cancer Disease Background and Overview
6. Non-Small Cell Lung Cancer Patient Journey
7. Non-Small Cell Lung Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Non-Small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of Non-Small Cell Lung Cancer Treatment
11. Non-Small Cell Lung Cancer Marketed Therapies
12. Non-Small Cell Lung Cancer Emerging Drugs and Latest Therapeutic Advances
13. Non-Small Cell Lung Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Non-Small Cell Lung Cancer Market Outlook (In US, EU5, and Japan)
16. Non-Small Cell Lung Cancer Companies Active in the Market
17. Non-Small Cell Lung Cancer Access and Reimbursement Overview
18. KOL Views on the Non-Small Cell Lung Cancer Market
19. Non-Small Cell Lung Cancer Market Drivers
20. Non-Small Cell Lung Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Traveler’s Diarrhea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Traveler’s Diarrhea market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Traveler’s Diarrhea market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology